Rising Antimicrobial Resistance encountered in high-risk leprosy patients, Suggests Study
A recent cross-sectional study published in the Indian Journal of Dermatology, Venereology, and Leprology in January 2026 reveals an alarming 17% antimicrobial resistance (AMR) rate among high-risk leprosy patients, underscoring an urgent clinical need for targeted genetic surveillance and transformative treatment strategies.
Driven by the rising clinical threat of drug-resistant Mycobacterium leprae, Dr. Rashmi Jindal and colleagues at the Himalayan Institute of Medical Sciences investigated primary and secondary antimicrobial resistance rates and their underlying genetic mutations in multi-bacillary leprosy patients.
Therefore, the prospective, cross-sectional study (July 2022–June 2024) at an Uttarakhand tertiary center evaluated 47 high-risk leprosy patients with a bacteriological index (BI) ≥2. Using slit skin smears, researchers employed PCR-based gene amplification to identify key resistance mutations in patients meeting specific clinical criteria, such as disease relapse or recurrent episodes.
Key Clinical Findings of he Study Includes:
• Significant Overall Resistance: Investigators successfully amplified 43 samples and identified an alarming 17% (8 cases) overall resistance rate to vital frontline medications like rifampicin, dapsone, and ofloxacin.
• High Primary Resistance: Researchers found a remarkable 20% (4 out of 20) primary resistance rate amongst treatment-naive individuals, indicating a concerning level of active transmission of drug-resistant strains within the community.
• Unique Rifampicin Mutations: Scientists discovered that every rifampicin-resistant patient exclusively harbored the F439L genetic mutation, a localized pattern that diverges significantly from the most common global resistance profiles.
• Link to Reactional States: Authors recorded that 10.5% of patients suffering from chronic or recurrent Erythema Nodosum Leprosum (ENL) exhibited resistance, reinforcing the necessity of screening those with persistent inflammatory reactions.
• Successful Treatment Modification: Clinicians demonstrated that transitioning rifampicin-resistant patients to a strategically modified Multi-Drug Therapy (MDT) comprising minocycline and ofloxacin yielded zero morphological indices (MI) and substantial clinical recovery.
The results suggest that an overall 17% antimicrobial resistance rate, heavily characterized by unique regional mutations like F439L, mandates the immediate deployment of molecular diagnostic tools. Such clinical shifts are essential for identifying hidden transmission networks and preventing widespread treatment failures.
These findings gently imply that practicing healthcare professionals might benefit from incorporating routine antimicrobial resistance screening for high-risk demographic subsets—especially those presenting with chronic reactions or persistent post-treatment bacterial loads—to carefully optimize and personalize ongoing therapeutic interventions.
The insights provided by the study are moderately constrained by the small regional sample size from a single tertiary institution and the technical inability to amplify every collected sample, highlighting a gentle necessity for future broad-scale multicenter studies and targeted animal model experiments to properly validate the functional implications of these identified genetic anomalies.
Reference
Jindal R, Singh I, Goyal D, Mittal A, Saini A, Dhoundiyal R et al. Resistance to anti-leprosy drugs in multi-bacillary leprosy patients: The need for transformative action. Indian J Dermatol Venereol Leprol. 2026;92:37-42
